|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, October 08, 2018 ) Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
Get Sample Copy of This Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-DPI-HnM-3117
The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.
Key Companies Covered in the Report are as follows
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate
Purchase Report@ https://www.qurateresearch.com/report/buy/HnM/QBI-DPI-HnM-3117/ (Priced at USD 1000)
Major and Promising Vaccine covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4. Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8. FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Enquiry about Report@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-DPI-HnM-3117
Table of Contents
1. Executive Summary
2. United States Influenza Vaccine Market & Forecast
3. United States Number of Persons Vaccinated with Influenza Vaccine
3.1 Number of Children Vaccinated
3.2 Number of Adults Vaccinated
4. United States Influenza Vaccine Market Drivers and Barriers
4.1 Market Drivers
4.2 Market Barriers
5. United States Influenza Vaccine Production & Distribution
5.1 Vaccine Choices Remain Available for Patients, Providers
5.2 Influenza Vaccine Price Trends
6. United States Influenza Vaccine Market – Regulatory Landscape
7. Market Dynamics – Mergers, Acquisitions, Key Agreements & Collaborations
7.1 Merger & Acquisitions
7.2 Collaboration Deal
7.3 Licensing, Exclusive & Distribution Agreement Deal
8. Influenza Vaccine – Pipeline Assessment
8.1 Promising Vaccine in Clinical Development
8.2 Promising Vaccine in Early–Stage Development
9. Influenza Vaccine – Clinical Trials Assessment by Phase and Trial Status
Enquiry for Customization@ https://www.qurateresearch.com/report/customize/HnM/QBI-DPI-HnM-3117
Qurate Business Intelligence
Nehal Chinoy
+919881074592
nehal@qurateresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
